A multi-institutional study demonstrated that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. Results also indicated that the biomarker test may detect recurrent disease earlier than imaging or other standard methods of post-treatment surveillance.
Parexel, one of the world’s largest clinical research organizations providing the full range of phase I to IV clinical development services, has released a new report in their expert series, New Medicines, Novel Insights.
